Filing Details
- Accession Number:
- 0001567619-21-007541
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-02 17:37:50
- Reporting Period:
- 2021-03-31
- Accepted Time:
- 2021-04-02 17:37:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501989 | Cytomx Therapeutics Inc. | CTMX | Pharmaceutical Preparations (2834) | 273521219 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1654058 | A. Sean Mccarthy | C/O Cytomx Therapeutics, Inc. 151 Oyster Point Blvd., Ste. 400 South San Francisco CA 94080 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-03-31 | 100,000 | $1.13 | 306,894 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-03-31 | 100,000 | $7.49 | 206,894 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-03-31 | 100,000 | $0.00 | 100,000 | $1.13 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 92,143 | 2021-09-20 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades in prices ranging from $7.35 to $7.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
